SEC Form 4 · accession 0002083206-26-000007
Lexeo Therapeutics, Inc. · LXEO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Louis Edward Tamayo
Officer — Chief Financial Officer
Period of report
Aug 18, 2026
Accepted (ET)
Aug 19, 2026 · 5:00 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001907108
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2,F3 | Aug 18, 2026 | S | 4,117 | $4.9071 | D | 92,907 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents a sale to cover tax obligations on the release of restricted stock units ("RSUs").
- F2This transaction was executed in multiple trades at prices ranging from $4.83 to $5.01. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- F3Includes 78,415 Restricted Stock Units.